Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20531445 | 1.00 | OR51E2 (0.40) | OR51E2AKR1B1 | |
| SCHEMBL18270956 | 1.00 | OR51E2 (0.40) | OR51E2AKR1B1 | |
| SCHEMBL14564211 | 0.73 | OR51E2 (0.59) | OR51E2AKR1B1 | |
| SCHEMBL9307587 | 0.73 | OR51E2 (0.59) | OR51E2AKR1B1 | |
| SCHEMBL9333820 | 0.73 | OR51E2 (0.59) | OR51E2AKR1B1 | |
| SCHEMBL23728418 | 0.72 | OR51E2 (0.46) | OR51E2 | |
| SCHEMBL8346473 | 0.72 | OR51E2 (0.46) | OR51E2 | |
| SCHEMBL7782071 | 0.72 | OR51E2 (0.46) | OR51E2 | |
| SCHEMBL11649679 | 0.72 | OR51E2 (0.46) | OR51E2 | |
| SCHEMBL12349812 | 0.72 | OR51E2 (0.46) | OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109402199-B | Method for synthesizing Globotriose by GH36 family alpha-galactosyltransferase | 沈阳农业大学 | 2022-05-10 | — | — | CN | disclosed |
| US-10596272-B2 | Vaccines against Streptococcus pneumoniae serotype 5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10301659-B2 | Cell-based production of nonulosonates | NATIONAL RESEARCH COUNCIL OF CANADA | 2019-05-28 | — | — | US | disclosed |
| US-20180296687-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-10-18 | — | — | US | disclosed |
| US-20170145459-A1 | Cell-Based Production of Nonulosonates | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-05-25 | — | — | US | disclosed |
| US-9512455-B2 | Cell-based production of nonulosonates | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2016-12-06 | — | — | US | disclosed |
| US-20140356912-A1 | CELL-BASED PRODUCTION OF NONULOSONATES | UNIVERSITY OF OTTAWA (CA) | 2014-12-04 | — | — | US | disclosed |
| EP-2379735-A1 | BIOSYNTHESIS OF CMP-LEGIONAMINIC ACID FROM FRUCTOSE-6-P, AND RESPECTIVE PATHWAY INTERMEDIATES, USING NOVEL GDP-LINKED PRECURSORS | National Research Council of Canada (CA) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069047-A1 | BIOSYNTHESIS OF CMP-LEGIONAMINIC ACID FROM FRUCTOSE-6-P, AND RESPECTIVE PATHWAY INTERMEDIATES, USING NOVEL GDP-LINKED PRECURSORS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296687-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | FUT5, SPAG5, IL5 | OR51E2 3906/4885AKR1B1 3338/4885 |
| US-10596272-B2 | Vaccines against Streptococcus pneumoniae serotype 5 | FUT5, SPAG5, IL5 | OR51E2 3906/4885AKR1B1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.